Elizabeth M Sherman

Memorial Healthcare System

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Paula Eckardt

Memorial Healthcare System

Melissa E. Badowski

University of Illinois Chicago

Nathan R. Unger

Gilead Sciences (United States)

Jason J. Schafer

Thomas Jefferson University

Sheila Montalvo

Memorial Health System

Timothy P. Gauthier

Baptist Health South Florida

Marylee V. Worley

Nova Southeastern University

Taylor K. Gill

University Health Care System

Kevin A. Clauson

Lipscomb University

Jennifer Cocohoba

University of California, San Francisco

Cooperative Institutions

Ibero American University

104

Nova Southeastern University

Memorial Healthcare System

University of California, San Francisco

University of North Carolina at Chapel Hill

University of Florida

Harvard University

San Francisco General Hospital

University of Illinois Chicago

Johns Hopkins University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

US Faculty Provide Infectious Disease Training to Doctor of Pharmacy Students and Faculty at Workshops in India

Elizabeth M Sherman M. Timothy Nelson K. Kiran Kumar Mark Decerbo P. Sivasankaran

Source

Cite

Citations (0)

Telemedicine Clinic to Expand Hepatitis C in a County Health Department

Elizabeth M Sherman

Source

Cite

Citations (0)

Advancing Transgender Health: Pharmacy Considerations in Cross-Gender Hormone Therapy

Elizabeth M Sherman

Hormone Therapy

Transgender Person

Source

Cite

Citations (0)

Influence of Health Insurance Status on Sustained Virologic Response for the Treatment of Hepatitis C Virus Infection Using Sofosbuvir-Based Antiviral Regimens: A Retrospective Study in a South Florida Community Hospital

Pauline Eckardt Andrew Savage Tracy Griffin Elizabeth M Sherman Junling Niu

Sofosbuvir

Source

Cite

Citations (0)

Overview of Hepatitis C Treatment in Minority Populations with HIV

Elizabeth M Sherman

Hepatitis C

Source

Cite

Citations (0)

Patient Perceptions of Text Messaging to Improve Antiretroviral Therapy Adherence: A Qualitative Study of Patients in a Ryan White Clinic

Journal of the International Association of Providers of AIDS Care (JIAPAC) (2018)

Elizabeth M Sherman Kevin A. Clauson Shara Elrod Paula Eckardt Fadi M. Alkhateeb

Evidence on the use of short message service (SMS) to improve medication adherence in people living with HIV (PLHIV) is mounting, yet qualitative research on patient perceptions regarding SMS content and utility for HIV/AIDS remains nascent. To explore the experience of receiving medication reminders via SMS among PLHIV, 45 uninsured and underinsured PLHIV nested within the intervention arm of a larger study received daily, 1-way SMS adherence reminders. Qualitative data were collected by face-to-face, structured interview and were analyzed using conventional content analysis methods. Three main themes emerged from the data: (1) reminders helping with adherence, (2) concerns about delivery modes, and (3) the need for confidentiality. Study findings offer enhanced focus on an emerging strategy in patient-centered HIV care: Equipped with greater context on the experiences of PLHIV using SMS adherence reminders, health-care providers can offer more targeted support and thereby maximize the benefits of this popular and powerful technology.

Underinsured

Short Message Service

Medication Adherence

10.1177/2325958218759209

Cite

Citations (9)

Current Trends in Antiretroviral Therapy

Elizabeth M Sherman

Source

Cite

Citations (0)

Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2019)

Kristina M. Brooks Elizabeth M Sherman Eric F. Egelund Amy L. Brotherton Spencer H. Durham

The era of the integrase strand transfer inhibitors ( INSTI s) for the treatment of human immunodeficiency virus ( HIV ) infection began with raltegravir in 2007. Since that time, several other INSTI s have been introduced including elvitegravir, dolutegravir, and, most recently, bictegravir, that have shown great utility as part of antiretroviral regimens in both treatment‐naive and treatment‐experienced patients. At present, antiretroviral guidelines fully endorse the INSTI class as part of all first‐line treatment regimens. After 10 years of experience with INSTI s, newer agents are on the horizon such as cabotegravir and MK ‐2048 for potential use as either HIV pre‐exposure prophylaxis or maintenance therapy. This review provides a brief overview of the INSTI class including agents currently available and those still in development, reviews available data from both completed and ongoing clinical trials, and outlines simplification strategies using INSTI s.

Dolutegravir

Raltegravir

Elvitegravir

Integrase inhibitor

10.1002/phar.2246

Cite

Citations (54)

Treatment of chronic hepatitis C virus infection with crushed ledipasvir/sofosbuvir administered through a percutaneous endoscopic gastrostomy tube in a patient with HIV coinfection

American Journal of Health-System Pharmacy (2020)

Vanessa Huffman Diana C. Andrade Elizabeth M Sherman Jianli Niu Paula Eckardt

Abstract Purpose Ledipasvir/sofosbuvir is an oral combination therapy containing fixed doses of direct-acting antiviral agents indicated for the treatment of hepatitis C virus (HCV) infection. Currently there are limited data on the clinical efficacy of crushed ledipasvir/sofosbuvir administered via feeding tube. Summary This case report discusses the successful treatment of chronic HCV genotype 1b infection with crushed ledipasvir/sofosbuvir administered through a percutaneous endoscopic gastrostomy (PEG) tube in a patient with human immunodeficiency virus (HIV) coinfection and high-grade sarcoma who had severe swallowing difficulties. The patient received crushed ledipasvir/sofosbuvir daily for a total of 12 weeks. At 12 weeks the patient had achieved a sustained virologic response. Conclusion Currently, ledipasvir/sofosbuvir is available only as a tablet, with limited pharmacokinetic data available to guide clinicians on use of the fixed-dose combination medication in crushed form. This case report highlights our experience treating a patient with HCV/HIV coinfection through administration of crushed ledipasvir/sofosbuvir via PEG tube, which we found to be a safe and effective therapeutic option.

Ledipasvir

Sofosbuvir

Percutaneous endoscopic gastrostomy

Hepatitis C

10.1093/ajhp/zxaa328

Cite

Citations (2)

HIV Treatment Guidelines and Antiretroviral Medications [Part 1]

Elizabeth M Sherman

Source

Cite

Citations (0)